Report: 1 in 5 will rebound after Paxlovid, but it still works
By
Kristen Fischer
Nov 14, 2023
One in five people who take nirmatrelvir/ritonavir (Paxlovid) get COVID-19 again after the drug clears them of it, according to a new study.
Wearable tech offers hope for spotting dementia-causing diseases
By
Kristen Fischer
Mar 08, 2024
Wearable technology that measures spatial navigation and gait could improve detection of diseases that cause dementia, according to a new study.
Paxlovid cuts COVID hospitalization, which may leave older adults weakened
By
Alicia Lasek
Dec 02, 2022
The CDC reports that COVID patients treated with the antiviral Paxlovid have a 51% lower risk of hospitalization, while another study has tied acute-care stays to muscle loss and long COVID.
Providers call for broader antipsychotic exclusions to help reduce schizophrenia diagnoses
By
Kimberly Marselas
Mar 31, 2023
Providers and quality experts are questioning why the agency hasn’t done more to review its quality measure for antipsychotic drug use.
CMS to begin audits for schizophrenia coding, says citations will affect quality ratings
By
Alicia Lasek
Jan 19, 2023
The agency will start auditing nursing homes this month to determine whether residents’ schizophrenia diagnoses are accurate and appropriately coded. A pattern of inaccurate coding may result in a quality...